The Corticobasal Syndrome Functional Rating Scale (CBD-FRS) is a specialized clinical assessment tool designed to measure functional impairment and disease severity in patients with corticobasal syndrome (CBS), a progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and movement abnormalities.
CBD-FRS is used to:
- Track disease progression over time
- Assess the severity of functional impairment
- Evaluate treatment efficacy in clinical trials
- Guide clinical management decisions
The scale is specifically tailored to capture the unique constellation of symptoms seen in CBS, including motor dysfunction, cognitive impairment, and behavioral changes.
¶ Domains Assessed
- Limb rigidity: Assessment of axial and appendicular stiffness
- Bradykinesia: Slowed movement and reduced spontaneous activity
- Dystonia: Involuntary muscle contractions and abnormal postures
- Myoclonus: Sudden, involuntary muscle jerks
- Apraxia: Loss of learned motor movements
- Executive dysfunction: Impaired planning, reasoning, and problem-solving
- Language impairment: Progressive aphasia and verbal fluency deficits
- Visuospatial dysfunction: Spatial orientation and constructional difficulties
- Memory: Working memory and episodic memory assessment
- ** Alien limb phenomena**: Feeling of foreignness in affected limbs
- Apathy: Reduced initiative and motivation
- Depression: Mood changes and emotional lability
- Disinhibition: Impulsive behaviors and poor judgment
- Activities of daily living (ADLs): Basic self-care tasks
- Instrumental ADLs: Complex tasks requiring multiple steps
- Mobility: Gait and balance function
- Communication: Speech and language effectiveness
The CBD-FRS typically uses a ordinal scale with scores ranging from 0 (normal function) to 4 or 5 (severe impairment), with higher scores indicating greater disability.
| Score |
Description |
| 0 |
Normal function |
| 1 |
Mild impairment |
| 2 |
Moderate impairment |
| 3 |
Severe impairment |
| 4 |
Complete loss of function |
Individual item scores are summed to generate total scores, which can be used to:
- Track disease progression
- Compare patients across studies
- Monitor treatment response
¶ Validation and Psychometric Properties
- Inter-rater reliability: Demonstrates moderate to good agreement between different assessors
- Test-retest reliability: Shows acceptable consistency over short intervals
- Internal consistency: Items demonstrate coherent measurement of the underlying construct
- Content validity: Items comprehensively cover the breadth of CBS symptoms
- Construct validity: Correlates with other established measures of motor and cognitive function
- Criterion validity: Predictive of functional outcomes and disease progression
- Demonstrates responsiveness to disease progression over time
- Can detect clinically meaningful changes in function
- Useful for monitoring treatment effects in clinical trials
CBD-FRS has been incorporated as a secondary endpoint in several clinical trials for CBS and related 4R-tauopathies, including:
- Tau inhibitor trials: Used to assess functional outcomes
- Neuroprotective agent studies: Monitoring disease modification
- Symptomatic treatment trials: Evaluating improvements in daily function
- Gene therapy investigations: Tracking functional endpoints
The scale is particularly valuable in trials targeting:
- Progressive supranuclear palsy (PSP)
- Corticobasal degeneration (CBD)
- Other 4R-tauopathies
CBD-FRS shares conceptual similarities with:
- MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale): For motor assessment
- MoCA (Montreal Cognitive Assessment): For cognitive screening
- ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living): For functional assessment
However, CBD-FRS is specifically designed to capture the asymmetric and heterogeneous presentation of CBS, which distinguishes it from more general Parkinson's plus syndrome scales.
- Complete assessment: 20-30 minutes
- Training required for standardized administration
- Typically administered by neurologists, movement disorder specialists, or trained research coordinators
- Requires understanding of CBS presentation and progression
- Baseline assessment at diagnosis
- Every 6-12 months for disease monitoring
- As needed for treatment decisions
- Asymmetric assessment: May not fully capture the lateralized nature of CBS
- Floor/ceiling effects: Some items may show limited range in early or late disease stages
- Inter-rater variability: Requires training to minimize scoring differences
- Limited validation data: Fewer validation studies compared to more established scales
Emerging developments include:
- Digital CBD-FRS: Integration with wearable sensors for objective measurement
- Computerized assessment: Tablet-based administration for standardized scoring
- Item response theory: Refinement of item weighting based on psychometric analysis
- Machine learning: Predictive modeling of disease progression